We compared combination therapy with low-dose aspirin plus ticlopidine to therapy with aspirin alone or ticlopidine alone in patients suffering transient ischemic attack or cerebral infarction. In 17,24, and 23 patients, respectively, 300 mg/day aspirin, 200 nig/day ticlopidine, and 81 mg/day aspirin plus 100 mg/day ticlopidine were administered orally. Aspirin alone markedly inhibited platelet aggregation induced by arachidonic acid, partially inhibited platelet aggregation induced by adenosine diphosphate, and did not inhibit platelet aggregation induced by platelet activating factor. Ticlopidine alone inhibited platelet aggregation induced by adenosine diphosphate and platelet activating factor, but did not inhibit platelet aggregation induced by arachidonic acid. Combination therapy with aspirin plus ticlopidine markedly inhibited platelet aggregation induced by all three agonists. Plasma concentrations of /3-thromboglobulin and platelet factor 4 remained unchanged by aspirin alone, were slightly reduced by ticlopidine alone, and were markedly reduced by aspirin plus ticlopidine. Plasma concentration of thromboxane B 2 was reduced by aspirin alone or with ticlopidine, but not by ticlopidine alone. The level of 6-ketoprostaglandin F l a was reduced only by aspirin alone. Bleeding time was significantly prolonged by aspirin alone and by ticlopidine alone, although the greatest prolongation was produced by aspirin plus ticlopidine. Our results indicate that the combination of aspirin plus ticlopidine is a potent antiplatelet strategy, although the clinical importance of the changes observed need to be determined by a properly designed and controlled prospective study. (Stroke 1989;20:1643-1647)
A tiplatelet agents have been used for the prevention of cerebral ischemia, 1 -6 and aspirin'- 4 and ticlopidine 5 ' 6 are the agents most widely used in Japan. A mean±SD 22±5% reduction in stroke or vascular death brought about by these agents has been shown in previous randomized trials. 4 Conversely, however, the trials show that these agents failed to prevent 73-83% of subsequent strokes and deaths. This partial failure in stroke prophylaxis might be attributable, at least in part, to these agents' incomplete inhibition of the multiple pathways leading to platelet aggregation. It is known that there are three different pathways leading to platelet aggregation. 7 - 8 The chemical mediators for these pathways are adenosine diphosphate - 8 Aspirin completely inhibits platelet aggregation induced by AA but inhibits only secondary platelet aggregation induced by ADP and PAF. On the other hand, ticlopidine inhibits both primary and secondary platelet aggregation induced by ADP and PAF, but its inhibition of platelet aggregation induced by AA is minimal. 8 We investigated combination therapy with aspirin plus ticlopidine since this combination can block all three pathways leading to platelet aggregation and may have a more effective antiplatelet activity than therapy with either aspirin or ticlopidine alone.
Subjects and Methods
We entered 72 patients who presented to our hospital between January 1986 and March 1988 into this study. The patients were randomly allocated to one of three groups (24 patients in each group). However, seven patients from the first group and one patient from the third group dropped out of the study. Four patients from the first group had to discontinue medication due to gastrointestinal symp-toms, three patients from the first group failed to attend the follow-up examination, and the patient from the third group discontinued medication after developing a skin rash.
Patients eventually assessed included 23 with transient ischemic attacks (TIAs) ( Platelet aggregation was measured in all patients by adding 2 /xM ADP (Niko Bioscience, Tokyo, Japan), 0.4 mM AA (Nakarai Kagaku, Tokyo, Japan), or 0.2 fjM PAF (Funakoshi Yakuhin, Tokyo, Japan) to platelet-rich plasma with a platelet count of approximately 2X10 5 cells/^1 and using an aggregometer (NKK Hematracer I, Niko Bioscience) based on turbidimetry as described previously.
9
- 10 The extent of platelet aggregation in platelet-rich plasma was expressed as the percent change in light transmission 5 minutes after adding the agonist. Platelet aggregation in whole blood was measured by stimulation with 10 /JM ADP, 1 mM AA, or 20 /nM PAF using an impedance aggregometer (Chrono-Log C540, Havertown, Pennsylvania). 8 - 10 The extent of platelet aggregation in whole blood was expressed as the impedance change (fl) 5 minutes after adding the agonist. Platelet-aggregation was measured both before and 1 week after starting medication.
Concentrations of /3-thromboglobulin (/3TG) and platelet factor 4 (PF4) in all patients were quantified by radioimmunoassay (RIA) using kits (Kaken Seiyaku, Tokyo, Japan, and Abbott Laboratories, North Chicago, Illinois, respectively) in plasma prepared from blood anticoagulated with ethylenediaminetetraacetic acid (EDTA) as described elsewhere. 11 In some patients from all three groups, thromboxane B 2 (TXB 2 ) and 6-ketoprostaglandin F l a (6-ketoPGF la ) were extracted according to the method of Green et al 12 and the concentrations of the two substances were quantified by RIA in plasma prepared from 7 ml venous blood anticoagulated with 10~4 M indomethacin, 10" 2 M EDTA, and 100 units aprotinin. Bleeding time was determined in some patients from all three groups with the Simplate device (Warner-Lambert, Morris Plains, New Jersey). 13 These platelet function tests were performed both before and 1 week after starting medication.
Platelet survival and lysis were measured in 10 normal subjects and in four patients from each group using [
m In]tropolone-labeled platelets both before and 2 weeks after starting medication. Fortythree milliliters of venous blood was collected in 7 ml acid citrate dextrose anticoagulant. The platelets were separated and labeled with indium-Ill according to the method of Dewanjee et al.
14 Nine milliliters of blood was collected in 1 ml EDTA 24, 48, 72, or 96 hours after the intravenous reinjection of the indium-lll-labeled platelets. Radioactivity of the samples was determined with a gamma well counter (JDC-772, Aloka, Mitaka, Japan). Platelet survival was determined using a least-squares exponential curve-fitting program.
14 Platelet lysis was calculated from the radioactivity of plasma-free indium-Ill with respect to total indium-Ill in samples of whole blood at 96 hours.
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The results were expressed as the mean±l standard deviation (SD) and were analyzed by Student's dependent t test to compare results after medication with those before medication. In addition, one-way analysis of variance was used to compare the three treatment regimens.
Results
There were no significant differences in platelet aggregation or function before medication. In plateletrich plasma, aspirin alone inhibited platelet aggregation induced by AA significantly more than did ticlopidine alone (p<0.01) but only partially inhibited platelet aggregation induced by ADP (/?<0.05) and did not significantly affect platelet aggregation induced by PAF (Table 1) . Ticlopidine alone markedly (significantly more than aspirin, p<0.01) inhibited platelet aggregation induced by ADP and PAF but did not significantly affect platelet aggregation induced by AA. Finally, aspirin plus ticlopidine inhibited platelet aggregation induced by all three agonists. No synergism or additivism between aspirin and ticlopidine was observed for the inhibition of platelet aggregation induced by any of the agonists because there was no significant difference in the inhibition of platelet aggregation between aspirin alone or ticlopidine alone and aspirin plus ticlopidine. Results obtained in whole blood were similar to those obtained in platelet-rich plasma, although the inhibition of platelet aggregation induced by ADP and PAF appeared to be less pronounced in patients treated with aspirin alone and more pronounced in patients treated with ticlopidine alone.
Plasma concentrations of /3TG and PF4 remained unchanged by aspirin alone (Table 2 ), but both were significantly reduced by ticlopidine alone, and an additional effect of aspirin when used concomitantly with ticlopidine was observed for /3TG (/?<0.05) but not for PF4. Plasma TXB 2 levels were greatly reduced by aspirin alone or with ticlopidine but not by ticlopidine alone (Table 2) . No additional effect of ticlopidine was observed when used concomitantly with aspirin. Plasma 6-ketoPGF la levels were significantly reduced only by aspirin alone. Bleeding time was significantly prolonged in patients treated with aspirin alone or ticlopidine alone, although the greatest prolongation was observed in patients treated with aspirin plus ticlopidine (p<0.05 vs. single agent) ( Table 2) .
Platelet survival and lysis were not significantly altered by treatment with aspirin alone or ticlopidine alone, whereas both measures were significantly affected by treatment with aspirin plus ticlopidine (Table 3) .
Hemorrhagic complications were observed in 13 patients. The complications included bruising in six, petechiae in two, epistaxis in two, hematuria in one, and hemorrhoidal and gingival bleeding in one patient each. Complications occurred in two patients treated with aspirin alone, in three patients treated with ticlopidine alone, and in eight patients treated with aspirin plus ticlopidine. Hemorrhagic complications tended to occur sooner (range 46-220, average 102 days) after starting medication in patients treated with aspirin plus ticlopidine than in patients treated with aspirin alone (157 and 206 days) or ticlopidine alone (172, 184, and 245 days). Bleeding time was prolonged (570-> 1,200 seconds) in all eight patients having hemorrhagic complications in whom it could be determined immediately. Platelet aggregation induced by ADP was inhibited in all eight patients with complications tested, whereas platelet aggregation induced by AA and PAF was inhibited in seven and six patients, respectively. The amount of blood lost was always small, and there was no significant fall of the hematocrit in any patient. No patient required a blood transfusion. The hemorrhagic complications subsided within a few days after discontinuation of the antiplatelet agents, and there was no evidence of intracranial hemorrhage in any patient.
Discussion
It has been shown by American, 1 Canadian, 2 and French 3 studies that aspirin can reduce the incidence of subsequent stroke and death in patients with TIA 1 -3 or even cerebral infarction. 3 The overview analysis of nine randomized trials (including those above) of aspirin for patients with ischemic stroke performed by the Antiplatelet Trialists' Collaboration showed that the risk reduction in the incidence of stroke, myocardial infarction, or vascular death produced by aspirin was 22% (SD 5%). This limited efficacy of aspirin appears to be at least in part attributable to its limited inhibition of the multiple pathways leading to platelet aggregation. 7 -8 We demonstrate that aspirin completely blocks platelet aggregation induced by AA, while it only partially inhibits platelet aggregation induced by ADP and has very little effect on platelet aggregation induced by PAF. We previously performed the first trial of ticlopidine for the secondary prevention of TIA.
S The dose of ticlopidine used in that trial was 200 mg/day (one 100-mg tablet b.i.d.), which is the usual dose in Japan, enough to suppress platelet aggregation in the average Japanese. 5 -6 In that study we demonstrated that the incidence of ischemic events was reduced by ticlopidine as well as that platelet aggregation induced by ADP was inhibited in patients with multiple episodes of TIA or reversible ischemic neurologic deficit (RIND). That pilot study was followed by a double-blind multicenter trial with ticlopidine and aspirin in patients with single or multiple TIAs. 6 The reduction in the incidence of subsequent stroke and myocardial infarction was not different between patients treated with 200 mg ticlopidine and those treated with 500 mg aspirin until 6 months after entry into the trial, but the reduction was significantly greater in patients treated with ticlopidine than in those treated with aspirin 12 and 36 months after entry. Two very large multicenter studies on the efficacy of ticlopidine in patients with cerebral ischemia were recently performed in North America. 17 One study involved >3,000 patients with TIA or RIND (Ticlopidine-Aspirin Stroke Study, TASS) 18 ; 500 mg/day ticlopidine or 1,300 mg/day aspirin was administered in a doubleblind trial for 2-6 (mean 3.3) years. The cumulative event rate for 3 years was significantly lower in the ticlopidine-treated group than in the aspirintreated group. In the other large trial, 1,000 patients with a completed thromboembolic stroke received 500 mg/day ticlopidine or placebo for up to 3 (average 2) years (Canadian-American Stroke Study, CATS). 19 -20 A 30% risk reduction of stroke, myocardial infarction, and vascular death was observed in the ticlopidine-treated group compared with the placebo-treated group.
The mode of action of ticlopidine in inhibiting platelet aggregation is not as clearly understood as that of aspirin, which is known to inhibit cyclooxygenase, thereby inhibiting the synthesis of thromboxane A 2 , a potent platelet-aggregating substance. Ticlopidine has been reported to activate adenylate cyclase, increasing the concentration of cyclic adenosine monophosphate and leading to the inhibition of platelet aggregation 21 or to produce a thrombasthenic state by inhibiting the binding of fibrinogen to platelets. 22 Ticlopidine can inhibit both primary and secondary platelet aggregation in response to ADP and PAF, but its inhibition of platelet aggregation in response to AA is not prominent since ticlopidine has no effect on cyclooxygenase. 5 -8 This was confirmed by our present study.
In our previous study 23 we investigated the relation between stroke recurrence and platelet aggregation in patients treated with aspirin or ticlopidine. Platelet aggregation induced by ADP was significantly inhibited after administration of these drugs in the group of patients without recurrence, but aggregation was not significantly inhibited in the group of patients who had a recurrent stroke. However, stroke still recurred despite the inhibition of platelet aggregation induced by ADP in some patients. One possible explanation for this discrepancy might be the presence of intact pathways for platelet aggregation via AA and/or PAF, although this could not be proven since platelet aggregation induced by AA and PAF was not measured in that study.
Therefore, we tried combination therapy with aspirin plus ticlopidine, which can inhibit all the pathways leading to platelet aggregation via ADP, AA, and PAF. The combination of aspirin plus ticlopidine inhibited platelet aggregation by all three agonists. Combination therapy also markedly reduced concentration of )3TG and PF4, whereas aspirin alone or ticlopidine alone did not affect or only slightly reduced them.
11
- 24 This shows that aspirin combined with ticlopidine can suppress in vivo platelet secretion, which cannot be suppressed when only one or two of the pathways leading to platelet aggregation are inhibited by aspirin alone or ticlopidine alone. In addition, the combination of aspirin plus ticlopidine produced a greater prolongation of bleeding time than did aspirin alone or ticlopidine alone. This is additional evidence that the combination can inhibit in vivo platelet function by inhibiting all pathways leading to platelet aggregation. Moreover, platelet survival was prolonged and platelet lysis was reduced after treatment with aspirin plus ticlopidine despite the fact that neither measure of platelet function was significantly altered after treatment with aspirin alone or ticlopidine alone. The correction of platelet survival and lysis by the combination therapy might reflect inhibition of the consumption and destruction of platelets in vivo. These results indicate that the combination of aspirin plus ticlopidine is a potent antiplatelet strategy, although the clinical importance of the changes that we observed need to be determined by a properly designed prospective controlled study for the secondary prevention of ischemic stroke.
On the other hand, hemorrhagic complications were observed more frequently among patients treated with aspirin plus ticlopidine than among those treated with aspirin alone or ticlopidine alone, despite the smaller doses we used since the combination of 300 mg/day aspirin plus 200 mg/day ticlopidine had produced frequent hemorrhagic complications in a preliminary study. Optimal doses of aspirin and ticlopidine in combination should be determined by further investigations to minimize the hemorrhagic complications while preserving the antithrombotic effect.
